KDL Inc. Report issue

For profit Phase 2
Founded: Hatfield PA United States (2011)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2011
NCT01039428
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

chitosan (1 trial)

vs-505 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperphosphatemia (Phase 2)

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2